BUSINESS

• Sanofi Japan Chief Iwaya to Step Down at June End, Leave EFPIA Role
  April 16, 2026

• Suntory to Acquire Daiichi Sankyo’s OTC Business for 246.5 Billion Yen
  April 16, 2026

• MSD Debuts HIV Drug Idvynso in Japan in World-First Launch
  April 16, 2026

• GSK’s Long-Acting Asthma Drug Exdensur Now Available in Japan
  April 16, 2026

• Asahi Kasei Confident of Hitting 2027 Profit Goal, Tarpeyo as Pharma Growth Driver
  April 16, 2026

• Sanwa Files Paltusotine in Japan for Acromegaly, Pituitary Gigantism
  April 16, 2026

• Shionogi’s CVC Makes First Investment in Restore Vision
  April 16, 2026

• Mochida Partners with Qilu on Gonal-f Biosimilar Development
  April 16, 2026

• Astellas Kicks Off Global PIII of KRAS G12D Degrader Setidegrasib
  April 16, 2026

• G1 Reform Will Accelerate LLP Transfers, Fuel Competition: LTL Chief
  April 15, 2026

• Daiichi Sankyo’s I-DXd Filed in US for SCLC, Wins Priority Review
  April 15, 2026

• Nxera’s Partner Earns Taiwan Approval for Daridorexant
  April 15, 2026

• Sanofi Japan Sales Rise 4.5% in 2025 as Dupixent Widens Label
  April 15, 2026

• Eylea Biosimilar Supply Curbed amid Originator Disruption
  April 14, 2026

• Novartis, JSH Begin Project to Address Regional Gaps in Hematology Care
  April 14, 2026

• Nxera to Receive US$22.5 Million Milestone as Schizophrenia Drug Enters PII
  April 14, 2026

• Itochu Unit to Import Sodium, Potassium Chloride from Germany
  April 14, 2026

• JCR Launches PIII Dose Comparison Study of Growject in Japan
  April 14, 2026

• AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
  April 13, 2026

• SSP Looks to Broaden Switch OTC Portfolio under New President
  April 13, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »